I
ITCI

InceptionR’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

InceptionR’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,375
Closed -$1.03M – 883
2024
Q4 		$1.03M Buy
+12,375
New +$1.02M 0.23% 152
2024
Q3 		– Sell
-12,055
Closed -$826K – 913
2024
Q2 		$826K Buy
12,055
+4,480
+59% +$311K 0.23% 151
2024
Q1 		$524K Buy
+7,575
New +$521K 0.13% 287
2023
Q1 		– Sell
-6,522
Closed -$345K – 617
2022
Q4 		$345K Buy
+6,522
New +$327K 0.18% 242

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

InceptionR's ITCI Position: Q1 2025 in Review

InceptionR sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 12,375 shares — an estimated $1.03M sold.

InceptionR first reported a position in ITCI in Q4 2022 and held it in 4 quarters. The position peaked at $1.03M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • InceptionR reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • InceptionR sold 12,375 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $1.03M.
  • InceptionR first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 4 quarters.
  • InceptionR's Intra-Cellular Therapies Inc. position peaked at $1.03M in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on InceptionR's 13F filing for Q1 2025, filed 12 May 2025.